sluit venster

Log in

Gebruikersnaam Wachtwoord Gebruikersnaam en/of wachtwoord vergeten? Gebruikersnaam en wachtwoord aanvragen

Zoek in de HOVON website

Let op!
Mogelijk ziet u niet alle beschikbare info op deze pagina, omdat u niet bent ingelogd, of omdat u niet de juiste privileges heeft.

Clinical picture: NHL (Non Hodgkin Lymphoma)

Trial: HOVON 47 NHL

1. Overview
Study details
2. Patient eligibility criteria
3. Registration (& randomization) of patients
4. Participating parties
5. Participating sites
6. Instruction videos
7. Download documentation / forms

return to top


No news

1. Overview


Chlorambucil versus 2 x 2 Gy involved field radiotherapy in stage III/IV previously untreated follicular lymphoma patients. A prospective, randomized phase III clinical trial.



Study details

Type of study

Prospective randomized Phase III study

Target number of patients


Date of activation


Approved by

CKTO: CKVO 2001 -01
MEC: PTC The Netherlands Cancer Institute 25-04-2001

Study objectives

To assess the effect of 2 x 2 Gy involved field radiotherapy compared with Chlorambucil with respect to progression free survival (PFS) and quality of life.
As secondary objectives the effect of 2 x 2 Gy involved field radiotherapy will be evaluated as regards complete remission rate, partial remission rate, overall survival, toxicity and compared to Chlorambucil.

2. Patient eligibility criteria

Inclusion criteria

Previously untreated Ann Arbor stage III and IV follicular lymphoma patients, grade I � III. (see appendices A and C)
Age 65 years or more, no upper limit.
WHO Performance Status 0 - 2. (see appendix E)
Nodal and extranodal sites, measurable bidimensionally on physical examination or diagnostic imaging.
Adequate haematological parameters at diagnosis: Hb >= 6.0 mmol/l, leukocytes >= 4.0 x 109 /l, thrombocytes >= 100 x 109 /l.
Written informed consent.

Exclusion criteria

Severe cardiac, pulmonary, neurologic, psychiatric or metabolic disease precluding either Chlorambucil chemotherapy or radiotherapy.
Patients with prior malignancies except basal cell carcinoma of the skin or carcinoma in situ of the cervix.
Patients unable to fulfil regular outpatient appointments both for treatment and follow-up.
Known HIV-positivity.
Known central nervous system or orbital NHL localisation.
Use of systemic corticosteroid medication (inhalation and topical corticosteroids are allowed).

3. Registration (& randomization) of patients


Central registration at the HOVON Data Center:
Erasmus MC Cancer Institute, Clinical Trial Center (Hs-423)
P.O. Box 2040
NL-3000 CA Rotterdam
Phone number.: +31.10.7041560 (working days 9.00-17.00)
Fax number.....: +31.10.7041028
TOP address...:

Registration criteria

The following information will be requested:

Protocol number
Institution name
Name of caller/responsible investigator
Patient�s initials or code
Patient�s hospital record number
Date of birth
Date of diagnosis of follicular lymphoma
PA number
Eligibility criteria.

4. Participating parties

Principal investigator

R.L.M. Haas (


W.L.J. van Putten (

Trial manager

C. van Hooije (

Central data management

C. van Hooije (

Other functions

Central Pathologist:
D. de Jong (

Please contact monitors at

5. Participating sites

Included patients *
NL-Amsterdam-Antoni van Leeuwenhoek ZH
NL-Amsterdam-Bovenij Ziekenhuis
NL-Amsterdam-Slotervaart Ziekenhuis
NL-Breda-Amphia ziekenhuis, locatie Langendijk
NL-Capelle a/d IJssel-IJsselland Ziekenhuis
NL-Delft-Reinier de Graaf Gasthuis
NL-Den Bosch-Jeroen Bosch ziekenhuis
Show 29 more...
* Please note that if TOP is not used to register patients for a study, the number of patients shown is zero.

6. Instruction videos

7. Download documentation / forms


return to top